CD274 and small cell lung carcinoma: Common biomarkers for immunotherapy, such as PD-L1 expression and TMB assays, are costly, time-consuming, and inadequate predictors for ES-SCLC outcomes (Wang et al. 2022; Reck et al. 2019; Antonia et al. 2016).